Staphylococcal resistance to linezolid (LZD) is mediated through ribosomal mutations (23S
The urgent need for new antibiotics is largely due to the increase in the frequency of bacterial infections with resistant strains, especially Gram-positive organisms, in both the hospital and community settings. Oxazolidinones are a relatively new class of antibiotics that inhibit bacterial protein synthesis by preventing binding of the aminoacyl-tRNA to the A site of the ribosome (30, 40) . The potential utility of members of this class include intravenous (i.v.), oral, and stepdown therapy, as well as activity versus multidrug-resistant infections. Linezolid (LZD) (Zyvox) is currently the only FDA-approved and marketed oxazolidinone (1) . Since entering the market in 2000, LZD has gained wide use clinically for treating infections caused by Gram-positive pathogens. There has been an ongoing effort to develop second-generation oxazolidinones (71) , and currently there are two in clinical development: TR-701 (torezolid phosphate; Trius Therapeutics, Inc.) and radezolid (RX-1741; Rib-X Pharmaceuticals, Inc.).
The structure-activity relationships (SAR) of oxazolidinones have been extensively reported, starting with the original oxazolidinone SAR developed at DuPont (25, 26, 54) , followed by SAR studies that led to the discovery of LZD by Pharmacia & Upjohn (5, 9, 10) (see Fig. 1 ). These studies demonstrated the key role of the 3-(3-fluorophenyl)-oxazolidinone rings and the 5-acetamidomethyl substituent. Later studies demonstrated that substituents in the 4 position of the 3-phenyloxazolidinone can enhance antibacterial potency, especially those containing a 3-aryl or heteroaryl ring (6, 31) . Some of the most potent compounds are the 3-biphenyloxazolidinones discovered by Rib-X (RX-1741, formerly known as Rx-01_667) (64, 78, 79) , the 3-(4-pyrid-3-yl)-phenyloxazolidinones discovered by Dong-A (DA-7867) (77) , Kyorin/Merck (AM-7359) (37, 52) , and AstraZeneca ("compound 13") (56) , and the 3-(azolylphenyl)-oxazolidinones from Pharmacia & Upjohn ("compound 4") (20) (Fig. 1 ). Continued exploration of the SAR of the oxazolidinone ring C-5 position has led to the discovery of alternatives to acylaminomethyl groups that maintain or enhance antibacterial potency, such as the 1,2,3-triazol-2-yl-methyl (55), pyrid-2-yl-oxymethyl, and isoxazol-3-yl-oxymethyl groups (23) . Although the initial 5-hydroxymethyl oxazolidinones examined by DuPont and Pharmacia & Upjohn were significantly weaker in potency than the 5-acylaminomethyl analogs, when combined with a potent ABCD ring system, the Dong-A scientists found that 5-hydroxymethyloxazolidinones such as DA-7157 (TR-700) ( Fig. 1) had excellent antibacterial activity (29) .
The emergence of LZD r strains soon after the approval of LZD (22, 69) necessitated the requirement of maintenance of good activity against clinically resistant strains for all secondgeneration oxazolidinones. To date, the most frequently reported type of LZD resistance involves target-based mutations which arise primarily in patients undergoing long-term therapy (11, 17, 22, 69, 74) . These mutations map to the domain V region of 23S rRNA genes (67) , as well as to the genes encoding the 50S ribosomal proteins L3 and L4 (rplC and rplD, respectively) (28, 42, 43, 75, 76) . Despite documentation of such target-based mutations, they remain infrequent in the clinic (18, 32, 34) . Previous studies of TR-700 and radezolid have demonstrated enhanced potency of these molecules against LZD-resistant (LZD r ) ribosomal mutants as a result of optimization of C-and D-ring systems (39, 42, 43, 63, 64) , although a thorough SAR analysis has not been reported.
In more recent years, LZD r strains possessing the cfr gene have emerged around the world (12, 13, 18, 19, 32, 35, 36, 47, 48, 51, 68) . Identification of a clinical strain carrying this novel cfr gene, previously seen only in veterinary isolates (46) , was first reported in an LZD r MRSA strain isolated in 2005 in Medellin, Colombia (68) . Through carbon-8 methylation of 23S rRNA base A2503 in the peptidyl transferase center (PTC) of the 50S ribosomal subunit, the Cfr methyltransferase greatly diminishes LZD binding, leading to MIC values in excess of the 4-g/ml breakpoint (21, 36) . Cfr methylation also confers resistance to phenicols, lincosamides, pleuromutilins, and streptogramin A antibiotics (46) , as well as 16-membered ring macrolides (66) . In addition to the potential for selection with multiple classes of 50S targeted antibiotics, Cfr is inherently more worrisome than target-based mutations because it is associated with horizontally transferable elements (2, 36, 46, 48, 49, 68) and has a low fitness cost (38) . The influence of Cfr methylation on the antimicrobial activity of members of the oxazolidinone class has not been fully explored. Previous studies have shown that TR-700 maintains its potency against cfr-positive strains (MIC 90 , 0.5 g/ml) (50) . Radezolid has demonstrated activity against a laboratory-generated Staphylococcus aureus cfr strain (MIC, 2 g/ml) (39); however, its activity against clinical cfr strains has not been reported.
In contrast to the well-described SAR for oxazolidinones for wild-type S. aureus strains, little is known about the SAR of oxazolidinones for LZD r strains. Furthermore, when such an SAR data set is reported, it is typically for a single compound and for a limited number of strains. To address this shortfall, we established the SAR of structurally diverse oxazolidinones for a panel of clinical and laboratory-derived S. aureus strains possessing ribosomal mutations or the cfr methyltransferase gene. We also modeled the binding of these compounds to the PTC using the Deinococcus radiodurans and Haloarcula marismortui 50S subunit crystal structures to gain insights into the observed SAR trends, with the goal of informing the development of second-generation oxazolidinones that balance potency and activity against clinically relevant resistance determinants.
( (68) , CM05⌬ (cfr-negative strain isogenic to CM05) (43), RN4220(pLI50) (contains the control vector pLI50) (68), RN4220(pLXM1) (pLI50 vector containing the cloned cfr gene under the control of a B. subtilis promoter, Pspac) (68), 29213(p42262) (contains the cfr plasmid p42262 isolated from 42262 and transformed into ATCC 29213 as previously described [59] ), and 42262 (MRSA; Spanish clinical isolate, plasmidborne cfr gene) (50) . All 23S rRNA alleles and rplC and rplD genes in clinical cfr isolates were amplified and sequenced as previously described (43) to ensure that no relevant 50S structural mutations were present which may have additionally contributed to reduced susceptibility to oxazolidinones.
Antimicrobial agents. Test solutions of TR-700 (torezolid; Trius Therapeutics, Inc., San Diego, CA), compound 1 (TR-700 B-ring difluoro analog), compound 2 (TR-700 C-5 acetamide analog), compound 3 (TR-700 D-ring 1,3,4-oxadiazole analog), compound 4 (TR-700 C-5 1,2,3-triazole analog) (Dong-A Pharmaceutical Co., Yongin, South Korea) equivalent to "example 1" of AstraZeneca U.S. patent 7,498,350 B2 (24), RX-1741 (radezolid; Medicilon, Chicago, IL), LZD (ChemPacific Corp., Baltimore, MD), and vancomycin (VAN) (Sigma-Aldrich Corp., St. Louis, MO) were freshly prepared in 100% dimethyl sulfoxide (DMSO) prior to use in MIC assays or selective medium (Fig. 1) . Quality control of oxazolidinones used in this study was performed via nuclear magnetic resonance (NMR), liquid chromatography-mass spectrometry (LC-MS), and biological activity assays.
MIC testing. MIC assays were performed via broth microdilution in accordance with CLSI guidelines (14) , and values were determined visually through detection with alamarBlue (Invitrogen Corp., Carlsbad, CA) as previously described (4). Enumeration of CFU was performed by serially diluting the assay inocula in phosphate-buffered saline (PBS) and plating on MHA. MIC values reported for each strain/drug combination were determined in at least three independent experiments, all yielding identical results.
Modeling analysis of SAR trends. Proposed structural effects for the SAR trends in this study were deduced using the coordinates of the Deinococcus radiodurans and Haloarcula marismortui LZD-bound 50S crystal structures (PDB accession codes 3DLL and 3CPW) (30, 73) . Sequence alignments showed that the regions of the 50S structures discussed in this study are highly conserved, so the structural rationales proposed would be expected to hold for S. aureus and other species. Docking studies were conducted using the LigandFit protocol (72) in the Discovery Studio software (Accelrys, Inc.). Both the 3DLL and 3CPW structures were examined, but only the 3CPW structure gave reasonable docking results, likely due to the higher resolution of the 3CPW structure. As a test of the docking protocol, LZD was docked into the 3CPW structure using the flexible ligand mode with minimization of the initial fit using Smart Minimizer. This routine provided a docked LZD pose that had a root mean square (RMS) of 0.46 Å compared to the X-ray structure, indicating the program can retrieve a predictive structure. In addition to LZD, the ABC ring system of TR-700 and compound 4 (triazole) were also docked into the 3CPW structure using the same LigandFit (72) protocol, and images thereof were generated using the PyMOL software program (16) . No satisfactory model was obtained with compound 4 (see Fig. 1 ).
RESULTS
A diverse set of oxazolidinones show similar potency shifts between LZD s control strains and isogenic LZD r ribosomal mutants. Seven oxazolidinones (Fig. 1) were tested against two sets of isogenic laboratory-derived S. aureus strains with mutations in 23S rRNA, ribosomal proteins L3 and L4, and NRS127, an LZD r clinical isolate containing an L3 mutation (42, 43) . Mutants demonstrated a 4-to 16-fold increase in the LZD MIC, resulting in resistance (MIC Ͼ 4 g/ml) in all but strain 33591-3, where only a 2-fold increase in the MIC was observed (L4 mutation). Compared to TR-700 and the hydroxymethyl analogs (compounds 1 and 3), the acetamide (compound 2) and 1,2,3-triazole C-5 (compound 4) substituents maintained 2-to 4-fold potency advantages against susceptible and isogenic LZD r ribosomal mutant strains (Table  1) , consistent with findings in previous studies (29) .
The most significant shift in MIC was observed with the 3-copy G2447T, G2576T, and G2576T/T2571C mutants (Table  1) . Both TR-700 and radezolid had an MIC of 4 g/ml versus the G2447T mutant; however, the difluoro analog of TR-700 (compound 1) demonstrated an MIC of 8 g/ml. TR-700, radezolid, and compound 3 had an MIC of 2 g/ml versus the G2576T mutant, whereas the MIC of compound 1 was again elevated an additional 2-fold to 4 g/ml ( 700 and compounds 1 to 4 had MICs of Յ2 g/ml against the LZD r clinical isolate NRS127 (L3 mutation). Overall, both TR-700 and radezolid performed well against these ribosomal mutants, with TR-700 equal to or 2-fold better than radezolid. TR-700 typically showed Ն4-fold potency advantages over LZD.
Potency of compounds with hydroxymethyl and 1,2,3-triazole C-5 substituents is unaffected by the presence or absence of Cfr methylation, while compounds containing the acetamide substituent demonstrate a 2-to 8-fold loss in activity. Previous studies comparing LZD and TR-700 demonstrated that TR-700 maintains potent activity against cfr-positive strains whereas LZD does not (33, 41-43, 50, 63) . To probe whether the acetamide substituent accounted for this difference, we compared various C-5 substituents (Fig. 1) against three isogenic cfr-carrying or -lacking strain sets (1 laboratory-derived and 2 clinical) ( Table 2) .
When an isogenic pair of RN4220 strains with or without a cloned cfr gene (68) were compared, a 2-to 4-fold increase in the MIC of acetamide-containing compounds was observed, with no change in the MIC of compounds containing a hydroxymethyl or a 1,2,3-triazole substituent ( Table 2 ). The MIC values for radezolid against RN4220(pLI50) and RN4220(pLXM1) are 2-fold lower than previously reported values for this laboratory-derived isogenic set (39) .
CM05 was the first documented clinical isolate carrying the cfr gene, which was shown to be present in the S. aureus chromosome (68) . Recent studies have shown that this isolate contains a mixture of strains that possess cfr (LZD r ) and ones in which the cfr gene and one copy of the adjacent ermB gene are deleted (LZD s ) (44) . The MICs of the isogenic, clonally pure CM05 (cfr-positive) and CM05⌬ (cfr-negative) strains are compared in Table 2 . In all cases, compounds with an acetamide (LZD, compound 2, and radezolid) demonstrated a 2-to 4-fold increase in the MIC against CM05 versus CM05⌬. However, compounds with hydroxymethyl (TR-700, compound 1, and compound 3) or 1,2,3-triazole substituents (compound 4) showed no difference in the MIC in the presence or absence of Cfr.
To examine SAR for strains possessing a clinically derived, plasmid-borne cfr gene, MICs were determined against 42262 a ATCC 29213 and ATCC 33591 isogenic mutant panels were generated through selection in the presence of LZD and/or TR-700. NRS127 is an LZD r clinical isolate. b Mutations in 23S rRNA genes (and mutant allele copy number) or in the ribosomal protein L3 or L4 are shown. c MICs (broth microdilution; CLSI) were determined against the oxazolidinone panel (Fig. 1) . VAN (a representative cfr-positive strain from an LZD r MRSA outbreak in Madrid, Spain [50] ) and 29213(p42262) (ATCC 29213 control strain transformed with the cfr plasmid isolated from 42262). MIC values for TR-700 and LZD of 0.5 g/ml versus 16 g/ml against these two strains (Table 2 ) are identical to the previously established MIC 90 for these two compounds against the entire collection of 18 clinical strains (50) . Acetamidecontaining compounds (radezolid and compound 2) showed a 4-fold higher MIC against the clinical 42262 isolate. MIC values for the 29213(p42262) strain increased 2-fold for radezolid and 4-fold for compound 2 over MIC values of the isogenic wild-type ATCC 29213 background (Table 2 ). For TR-700 and compounds 1 to 4, there is a small potency advantage for the acetamide (compound 2) compared to the activity of the hydroxymethyl compounds (TR-700, compound 1, and compound 3) on the 29213 control strain; however, for the acetamide compounds, this potency advantage is lost in the presence of the cfr gene. Despite the presence of a C-5 acetamide in radezolid, MIC values against cfr strains for this compound fall between those of the hydroxymethyl analogs (TR-700 and compounds 1 and 3) and LZD, likely because of additional binding interactions (CD-ring system) with the upper region of the PTC (64) . Interestingly, the TR-700 ABCDring system containing a triazole (compound 4) had the lowest MIC values against both the cfr-negative and cfr-positive clinical strains.
DISCUSSION
The discovery and development of new oxazolidinones have remained challenging, due to the need to maintain favorable absorption, distribution, metabolism, and excretion properties and solubility while securing improvements in safety and efficacy. The SAR data herein build on earlier studies and highlight structural areas of interest in the design of oxazolidinones in order to address the evolving variety of resistance mechanisms documented for this anti-infective class.
Prior SAR studies have clearly demonstrated the positive contribution of the acetamidomethyl side chain (65) , as seen in LZD, to antimicrobial potency, with NOH acting as a hydrogen bond donor essential for interactions with the ribosome binding site (5, 23, 25, 26, 53, 54 ). As such, this group has been retained in oxazolidinones, having undergone significant development efforts (eperezolid, RWJ-416457, and radezolid). Although many other heterocyclic substitutions were poorly tolerated (58), certain analogs, such as the 1,2,3-triazoles from AstraZeneca ("compound 2" [57] and "example 1" [24] ) and Kyorin/Merck (AM-7359) (37, 52) showed good activity, possibly due to different binding modes in the ribosome (57) . Thus, in addition to the 1,2,3-triazole, there is now significant interest in other A-ring C-5 substituents, such as the hydroxymethyl (torezolid) group.
In this study, the activities of compounds with three different A-ring C-5 substituents were evaluated against strains possessing mutations in 50S structural components or carrying the cfr methyltransferase gene. Comparing TR-700-series analogs revealed that both acetamide and triazole groups confer small potency advantages (2-fold and 2-to 4-fold, respectively) over hydroxymethyl substituents against all classes of 50S mutationbased resistance determinants characterized to date (23S rRNA, L3, and L4). Evaluation of variable C-5 substituents against cfr strains, however, revealed a sensitive SAR, suggesting interactions between these substituents and the Cfr-methylated A2503 base. Docking the ABC ring systems of TR-700 and LZD, which vary in the C-5 position, provided an explanation for the MIC data with the cfr strains (Fig. 2) . In an unmethylated (wild-type) ribosome, the hydroxymethyl group of TR-700 docked in a fashion wherein the AB-rings replicated the interactions of LZD in the X-ray structure ( Fig. 2A and C) . The hydroxyl group formed a hydrogen bond to the same phosphate oxygen (G2540 in the 3CPW structure) that LZD binds to (30) . Base A2503, highlighted in stick form (Fig. 2) , is positioned adjacent to the pocket occupied by the acetamide of LZD or the hydroxymethyl of TR-700 ( Fig. 2A and C) . To model the Cfr methylation, a methyl group was added to A2503 (3CPW structure) (30) . Subsequently, we were unable to retrieve a docked pose for LZD that maintained the binding to the key phosphate oxygen (G2540). Overlay of the methylated model structure with the X-ray coordinates of the LZD bound to the PTC demonstrated the potential for a significant steric clash between the acetamide and the methyl group on the carbon-8 of A2503 (Fig. 2B) . In contrast, docking TR-700 demonstrated a similar pose in both the wild-type and the Cfr-methylated ribosome models, without any steric clashes a MICs (broth microdilution; CLSI) were performed against the oxazolidinone panel (Fig. 1) . VAN ( Fig. 2C and D) . The data in this study showed that both the triazole-and hydroxyl-containing compounds maintain full potency against the clinical cfr isolates. For the hydroxyl-containing compounds, the excellent potency on cfr strains is readily explained by the ability of this smaller substituent to easily fit adjacent to the methylated carbon-8 of A2503 without any steric overlap (Fig. 2D) . Alternative docking poses of the triazole analog (compound 4) could not explain the increased potency of this group, suggesting additional conformational adjustments of the bases of the PTC (data not shown).
Although the MICs of acetamide-containing compounds increase approximately 4-fold in strains carrying the Cfr methyltransferase, the steric clash observed in the modeling studies suggests that some conformational movement at the active site is necessary for the acetamide-containing compounds to have any activity at all. One possibility is that A2503 rotates, as seen in many (non-Cfr-methylated) antibiotic-bound D. radiodurans structures, such that the 8-methyl is positioned away from the PTC (7, 15, 27, 60, 61) . In the methylated state, this "out" conformation would be energetically unfavorable (relative to the unmethylated state) due to subtle but necessary accommodating movements of the RNA backbone. However, it would allow for binding of the acetamide compounds, albeit with greatly diminished potency relative to the hydroxyl-containing oxazolidinones, that would not require this conformational change. The MIC data reported here are consistent with this hypothesis.
Modeling suggests that the binding of the triazole-substituted compound 4 would also require the rotation of the 8-methyl of A2503 away from the PTC, as described above. However, the low MICs observed for this compound suggest that it gains additional interactions that compensate for the somewhat energetically unfavorable "out" rotation of methylated A2503. The known SAR of compound 4 shows that the 3-nitrogen of the triazole group is crucial to its potent MICs and therefore likely functions as a key hydrogen bond acceptor for interaction with the PTC (29) . The free hydroxyl groups of A2503 or G2505 represent reasonable candidates for this interaction, and both have previously been found to participate in ribosome-antibiotic hydrogen bond interactions. Specifically, lankacidin and a subset of pleuromutilins hydrogen bond with the hydroxyl of A2503 (3, 15) , and clindamycin and dalfopristin have been found to interact with that of G2505 (27, 62, 70) .
Previous modeling of oxazolidinones bound in the 50S subunit has revealed that C-and D-ring groups likely gains additional interactions with more highly conserved 23S rRNA bases, such as U2585 (63, 64) , supporting their role in the SAR described here. MIC data from both the ribosomal mutant and cfr strains revealed that C-and D-rings play a critical role in activity against all strain types. Among the TR-700 analogs, the 1,3,4-oxadiazole (compound 3) and the methyltetrazole (TR-700) were equipotent against all strains tested. The rank order (from least to most potent against both susceptible and resistant strains) of the three acetamide oxazolidinones examined in this study is LZD, which lacks a D-ring substituent, followed by radezolid, followed by compound 2. The 2-to 4-fold potency advantage of compound 2 over radezolid and the potency advantage of TR-700 over radezolid against the majority of strains tested here suggest that the CD-ring system in radezolid does not bind to the target as tightly as does the CD-ring system in the TR-700 analog series. Both TR-700 and radezolid, however, are intrinsically more potent than LZD, supporting the theory that D-ring substituents provide a potency advantage against all strain types.
Additional crystallographic studies demonstrating PTCbound oxazolidinones would greatly enhance the interpretation of SAR data. A more complete understanding of the SAR behind LZD resistance derived from existing tools, however, is still very useful for informing the development of second-generation oxazolidinones which maintain activity against a variety of resistance mechanisms, including Cfr methylation. This is of high priority now that cfr and all three ribosomal mutationbased resistance mechanism classes have been found to cooccur in clinical staphylococci (including cfr plus 23S rRNA [13] , cfr plus L4 [8] , and cfr plus L3 [45] ), resulting in exacerbated reduced susceptibility to oxazolidinones, particularly those containing C-5 acetamide substituents.
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